Navigating the Chinese Patent System: What U.S. Patent Counsel Need to Know, Leveraging Recent Amendments

Mr. Lian is a Senior Attorney with the China team at the Office of Policy and International Affairs of the USPTO. In that capacity, he provides legal and policy advice on domestic and international IP issues, focusing on patent, pharmaceutical and licensing issues. He also manages the China Resource Center, which was established under the USPTO Strategic Plan to develop and advocate empirical data analysis to guide USPTO initiatives and policy recommendations. Before joining the USPTO, Mr. Lian was in private practice with Foley & Lardner and Syncoda Technologies. His practice focused on patent law as well as food and drug law. Prior to switching his career into law, he worked as a scientist with three leading biopharmaceutical companies.

Mr. Moga has over 30 years of experience in domestic and international intellectual property portfolio development and enforcement. He is an experienced patent prosecutor in the mechanical, chemical, biochemical, and pharmaceutical arts and has been qualified and has testified as an expert witness in patent disputes. As an intellectual property portfolio developer, Mr. Moga’s experience includes the development of domestic and foreign patent portfolios, the acquisition of registrations for trademarks and copyrights, licensing, and policy development.

Dr. Qin has extensive experience as a patent attorney. Focusing her practice on all aspects of patent and trademark prosecution, procurement and transaction, Dr. Qin has advised Fortune 500 companies, universities, start-ups, and individual inventors to identify, capture, and protect innovations. Prior to joining Rimon, she was an in-house counsel at IHHI, a start-up company engaged in nuclear energy research and development. As an in-house counsel, Dr. Qin helped to establish the company’s IP program, working with the engineering team on validation of their innovations. She was pivotal in the establishment of a multi-prong IP protection strategy aimed to protect the company’s business interests, regarding patents and trade secrets.

Ms. Wang is Chief Executive Officer, Co-Founder of Steelike, Inc,

based in Springfield, Virginia. Steelike supplies a proprietary ultra-high

performance composite material, known as Steelike® UHPC, for the

construction, repair, preservation, and protection of infrastructures. Prior to Steelike, Ms. Wang was Deputy Executive Director for Regulatory Affairs of the American Intellectual Property Law Association (AIPLA), based in Arlington, Virginia where she served as a senior advisor to the Executive Director, and had principle day-to-day responsibility for AIPLA's domestic and international intellectual property policy work and regulatory issues of concern to the Association. Ms. Wang serves as an Advisor on the International Trade Advisory Committee, a unique public-private partnership jointly managed by the U.S. Department of Commerce and the Office of United States Trade Representative (USTR), engaged in formulating U.S. trade policy. She is a member of the Board of Directors of the National Inventors Hall of Fame. In addition, Wang is the Continuing Author of the Baxter, World Patent Law and Practice treatise, published by Matthew Bender & Company, a LexisNexis company.